AACR annual meeting to feature UNC Lineberger research

UNC Lineberger researchers and trainees will present nearly 20 research talks and presentations at the 2022 American Association for Cancer Research, April 8-13, at the Ernest N. Morial Convention Center in New Orleans.

The meeting, which will occur in person for the first time since 2019, draws together some 20,000 attendees from around the world and features presentations on the latest advances in basic, translational, and clinical cancer research.

The UNC Lineberger presentations include:

 

Saturday, April 9

Education Session

ED049 – The Importance of Surgeon Engagement for Translational Cancer Research

12:30 – 2 p.m.    |    Room 217-219, Convention Center

1 – 1:20 p.m.: Through the lens of a surgeon

Jen Jen Yeh, MD

 

Sunday, April 10

Symposium

SY10 – Adipose Tissue as a Driver of Carcinogenesis

1 – 2:30 p.m.   |    Room 217-219, Convention Center

1:05 – 1:25 p.m.: Disrupting the adipose-tumor link in experimental models of obesity-driven colon and breast cancer

Stephen D. Hursting, PhD

---

Poster Session

PO.IM02.07 – Immune Checkpoints

1:30 – 5 p.m.    |    Section 38

612 / 22 – Microbial determinants of immune checkpoint inhibition response in a murine model of obesity and metastatic basal-like breast cancer

Tori L. McFarlane

---

PO.PR01.01 – Preclinical Prevention, Early Detection, and Interception 1

1:30 – 5 p.m.    |    Section 1

14/14 – Resolution of obesity-driven proinflammatory adipose signaling by weight loss or an NSAID is associated with reduced tumor burden in a mouse model of colon cancer

Elaine M. Glenny, PhD

 

Monday, April 11

Advances in Organ Site Research Session

AOS02 – Triple Negative Breast Cancer: Molecular Insights and Treatment Advances

12:30 – 2 p.m.    |    Room 265-268, Convention Center

12:57 – 1:15 p.m.: Challenges of triple negative breast cancer: From the individual to the community     

Lisa A. Carey, MD, FASCO

---

Poster Session 

PO.TB01.01 – Genetically Engineered Mouse Models 1

9 a.m. – 12:30 p.m.    |    Section 10

921 / 11 – The Nrf2^E79Q activating mutation accelerates growth of pure-small cell lung cancer but not combined small cell lung cancer Tp53^{floxed/floxed}/Cdkn2a^{floxed/floxed} mice

Samera Hamad, PhD

---

PO.TB01.01 – Genetically Engineered Mouse Models 1

9 a.m. – 12:30 p.m.    |    Section 10

919 / 9 – APOBEC3 promotes tumor progression, squamous differentiation and metastasis in bladder cancer mouse model

Andrew S. Truong

---

PO.TB01.05 – Cell Line and Animal Models

1:30 – 5 p.m.    |    Section 11

1627 / 19 – Metabolic links between obesity and ferroptosis in a murine model of breast cancer

Emily Devericks

---

PO.CL06.05 – Inflammation / Modifiers of the Tumor Microenvironment

1:30 – 5 p.m.    |    Section 32

1995 / 7 – β-Hydroxy-β-methylbutyrate promotes immunotherapy response and pro-inflammatory macrophage polarization in a mouse model of pancreatic cancer

Michael F. Coleman, PhD

 

Tuesday, April 12

Poster Session

PO.MCB08.02 – Tumor-associated Metabolic Changes

9 a.m. – 12:30 p.m.    |    Section 8

2376 / 5 – Pyruvate carboxylase regulates mammary tumor microenvironment composition via central carbon metabolism

Alexander J. Pfeil

---

PO.BCS02.01 – Mathematical Models

1:30 – 5 p.m.    |    Section 29

2739 / 10 – Defining and evaluating drug additivity in clinical trials of combination cancer therapy

Haeun Hwangbo

---

PO.ET06.02 – Epigenetic Targets

1:30 – 5 p.m.    |    Section 23

3267 / 9 – ARID1A mutated bladder cancer cells are sensitized to BET protein inhibition with OTX-015

Ryan M. Kemper

---

PO.MCB02.01 – Non-apoptotic Cell Death / Autophagy

1:30 – 5 p.m.    |    Section 5

3010 / 17 – Targeting metabolic pathways through pharmacological and chemotherapeutic interventions to improve triple-negative breast cancer therapy

Alyssa N. Ho, MS

---

PO.TB06.05 – Secreted Soluble Factors and Exosomes in the Microenvironment

1:30 – 5 p.m.    |    Section 11

3128 / 6 – Paracrine adipocyte signaling promotes colorectal cancer growth in vitro

Nivetha S. Ramasamy

---

PO.IM02.16 – Immunomodulatory Agents and Interventions 2

1:30 – 5 p.m.    |    Section 37

3507 / 9 – β-Hydroxy-β-methylbutyrate (HMB) sensitizes murine pancreatic ductal adenocarcinoma (PDAC) to immunotherapy

Suhas K. Etigunta

---

Mini Symposium

Late-Breaking Research

2:30 – 4:30 p.m.    |    Room 217-219, Convention Center

3:20 – 3:35 PM: LB176 / 4 – Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network identifies microenvironment features as drivers of metastasis

Susana Garcia Recio, PhD

 

Wednesday, April 13

Poster Session

PO.ET04.03 – Molecular Classification of Tumors

9 a.m. – 12:30 p.m.    |    Section 25

4009 / 3 – Interaction between NF-κB and NRF2 pathways lead to improved outcomes in HPV-associated head and neck cancer

Aditi Kothari, MS

---

PO.TB10.03 – Clonal Evolution

9 a.m. – 12:30 p.m.    |    Section 11

3789 – Mapping lesion specific response and relapse patterns in metastatic colorectal cancer patients

Jiawei Zhou